CVSCVS HEALTH Corp

NYSE cvshealth.com


$ 59.53 $ 3.56 (6.35 %)    

Friday, 31-May-2024 15:59:56 EDT
QQQ $ 454.82 $ -0.01 (-0 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.59 (0.88 %)
TLT $ 91.26 $ 0.69 (0.77 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 59.6
$ 56.04
$ 0.00 x 0
$ 0.00 x 0
$ 55.82 - $ 59.56
$ 52.77 - $ 81.71
22,281,752
na
75.51B
$ 0.77
$ 10.31
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-07-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-08-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-04-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-18-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-02-2018 03-31-2018 10-Q
26 02-14-2018 12-31-2017 10-K
27 11-06-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-02-2017 03-31-2017 10-Q
30 02-09-2017 12-31-2016 10-K
31 11-08-2016 09-30-2016 10-Q
32 08-02-2016 06-30-2016 10-Q
33 05-03-2016 03-31-2016 10-Q
34 02-09-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 08-04-2015 06-30-2015 10-Q
37 05-01-2015 03-31-2015 10-Q
38 02-10-2015 12-31-2014 10-K
39 11-04-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-overweight-on-cvs-health-lowers-price-target-to-86

JP Morgan analyst Lisa Gill maintains CVS Health (NYSE:CVS) with a Overweight and lowers the price target from $101 to $86.

 baird-initiates-coverage-on-cvs-health-with-neutral-rating-announces-price-target-of-61

Baird analyst Michael Ha initiates coverage on CVS Health (NYSE:CVS) with a Neutral rating and announces Price Target of $61.

 are-boomers-crashing-the-economy-or-saving-it-why-investors-are-perplexed-and-what-you-can-do-to-prepare

Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest w...

 cvs-health-seeks-private-equity-partner-for-oak-street-health-expansion

CVS Health seeks a private equity partner to fund the expansion of Oak Street Health, acquired for $10.6 billion. This joint ve...

 cvs-reportedly-seeking-investor-to-back-new-oak-street-clinics

- Bloomberg

 unitedhealths-optumrx-unveils-new-transparent-drug-pricing-initiative-for-2024

UnitedHealth's OptumRx will implement a new pricing model, OptumRx Clear Trend Guarantee, starting next year.

 cvs-pharmacy-reveals-launch-of-well-market-a-new-store-brand-consumables-line-featuring-snacks-beverages-and-groceries

Most items in the Well Market line are priced between $2.99 to $8.99

 argus-research-maintains-buy-on-cvs-health-lowers-price-target-to-80

Argus Research analyst Chris Graja maintains CVS Health (NYSE:CVS) with a Buy and lowers the price target from $100 to $80.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION